The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / ACR/ARHP Annual Meeting 2012: Late-Breaking Abstracts Bring Newer Research to the Forefront

ACR/ARHP Annual Meeting 2012: Late-Breaking Abstracts Bring Newer Research to the Forefront

January 1, 2013 • By Mary Beth Nierengarten

  • Tweet
  • Email
Print-Friendly Version / Save PDF

WASHINGTON, D.C.—Several studies were presented during a late-breaking abstract session here at the 2012 ACR/ARHP Annual Meeting, held November 9–14. Turn to page 37 for some highlights from the session.

You Might Also Like
  • ACR/ARHP Annual Meeting 2012: New Research Into Stem Cell Therapy and Drugs May Lead to Breakthrough Treatments for Osteoarthritis
  • ACR/ARHP Annual Meeting 2012: New Research Delves Into the Risk of Comorbidities for Patients with Lupus
  • ACR/ARHP Annual Meeting 2012: Fatigue for People with Rheumatoid Arthritis Rooted in Physiological and Psychological Factors
Explore This Issue
January 2013
Also By This Author
  • Institute for Clinical Economic Review Final Report on RA Treatments

Reducing Dose of Etanercept Effective in Reducing RA Flares in Select Patients

Ronald F. van Vollenhoven, MD, PhD, professor and chief of the unit for clinical therapy research, inflammatory diseases and chief of the clinical trials unit in the department of rheumatology at the Karolinska Institute in Stockholm, Sweden, presented results of the Dose Reduction or Discontinuation of Etanercept in Methotrexate-Treated Rheumatoid Arthritis Subjects Who Have Achieved a Stable Low Disease Activity-state (DOSERA) trial. The randomized, double-blind, multicenter study was undertaken to assess the effect of discontinuing or reducing the dose of etanercept (ETN) in patients with rheumatoid arthritis (RA) being treated with combination ETN and methotrexate (MTX)

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The study included 73 patients with RA treated with ETN (50 mg weekly) plus MTX (stable dose, 7.5–25 mg/week) and who had maintained low disease activity/remission as measured by Disease Activity Score (DAS) 28 <3.2 for at least 11 months. To be eligible for the study, patients also had to be at least 18 years old with no prior treatment with non–antitumor necrosis factor (TNF) biologic agents or no prior attempt to discontinue ETN due to stable disease. Patients were randomly assigned to continued therapy with the same dose of ETN (50 mg weekly; n=23), a reduced dose of ETN (25 mg/weekly; n=27), or placebo (n=23) while continuing with MTX.

The primary endpoint of the study was the proportion of nonfailures at 48 weeks between patients treated with ETN (50 mg/week) versus placebo. Failure was defined as DAS28 >3.2 and an increase in DAS28 >0.6 or disease progression. A comparison of nonfailure and DAS28 outcomes for all three groups was also made.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Overall, the results showed that patients who maintained the full ETN dose (50 mg) and the reduced dose (25 mg) had response better than the placebo group. The study found that the proportion of nonfailures at 48 weeks was 52% for patients who continued on ETN (50 mg/week) versus 13% for those on placebo, with an odds ratio (OR) of 7.2 (95% CI, 1.7–29.8; P=0.007). The proportion of nonfailures for patients who continued on the reduced ETN (25 mg/week) dose was 44% versus 13% for placebo, with an OR of 4.2 (95% CI, 1.0–17.0) (P=0.044).

Although ETN at 25 mg/week is not yet an approved dose of ETN, Dr. van Vollenhoven said that the findings of the study suggest that it may be worthwhile for rheumatologists to try the reduced 25 mg/week dose of ETN in their patients to maintain low disease activity. He said the risk of doing this seems small given that the study also showed that patients who had a flare at the reduced dose and were treated again at the higher dose were able to regain low disease activity.

Pages: 1 2 3 4 5 | Single Page

Filed Under: Conditions, Meeting Reports, Rheumatoid Arthritis Tagged With: ACR/ARHP Annual Meeting, Psoriatic Arthritis, RA flares, Rheumatoid arthritisIssue: January 2013

You Might Also Like:
  • ACR/ARHP Annual Meeting 2012: New Research Into Stem Cell Therapy and Drugs May Lead to Breakthrough Treatments for Osteoarthritis
  • ACR/ARHP Annual Meeting 2012: New Research Delves Into the Risk of Comorbidities for Patients with Lupus
  • ACR/ARHP Annual Meeting 2012: Fatigue for People with Rheumatoid Arthritis Rooted in Physiological and Psychological Factors
  • ACR/ARHP Annual Meeting 2012: Genes Not the Only Factor in Susceptibility to Rheumatoid Arthritis

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)